Pfizer contemplates cost-cutting measures amid slower COVID-19 product sales and upcoming booster rollout

USA – In an unforeseen twist, Pfizer, the pharmaceutical giant, is facing the possibility of implementing cost-saving strategies later this year due to sluggish sales of its COVID-19 vaccine and antiviral drug.

This move is prompted by a subdued demand projection extending into the fall season, when the company plans to introduce an upgraded booster shot.

This revelation, which emerged recently, coincided with Pfizer’s release of its second-quarter earnings report.

The data disclosed a significant 53% year-over-year drop in revenue, attributed to a decrease in demand for Pfizer’s partnered vaccine, Comirnaty, developed alongside BioNTech, and its COVID-19 pill, Paxlovid.

Remarkably, excluding these two products, Pfizer still managed to achieve a 5% growth in overall revenue.

Pfizer enjoyed a lucrative streak in 2021 and 2022, fueled by the widespread utilization of Comirnaty and Paxlovid, as well as strategic government stockpiling.

These ventures resulted in substantial financial gains, empowering Pfizer to acquire multiple biotechnology firms and uphold its commitment to shareholders through dividends.

However, the landscape has shifted due to a decrease in COVID-19 vaccine administration, aligned with declining infection rates in the United States and Europe.

Concurrently, the U.S. government has eased its bulk purchasing approach, transitioning sales and distribution into the commercial sphere.

This change in demand dynamics has created uncertainty for Pfizer in predicting the future revenue generated by Comirnaty and Paxlovid.

This unpredictability was acknowledged by company executives, who contemplated the potential need for cost-cutting measures in the upcoming period.

Pfizer’s Chief Financial Officer, David Denton, emphasized the pivotal role that this fall’s performance of COVID-19 products would play in refining sales forecasts.

He asserted, “To that end, if our COVID-19 revenues are less than what we assumed, we are prepared to launch an enterprise-wide cost improvement program aligned with the longer-term revenue projections for our business.”

Pfizer’s CEO, Albert Bourla, further delineated that any cost-reduction strategies, if deemed necessary, would likely concentrate on the company’s “COVID-19 cost base.”

The decline in sales of COVID-related products aligns with Pfizer’s prior projections of reduced revenue for the current year compared to the previous year.

Despite this anticipated slowdown, the company maintains its forecast of US$21.5 billion in combined sales for Comirnaty and Paxlovid throughout the entire year.

Pfizer also anticipates a surge in sales during the fall season, traditionally marked by a rise in infections.

On another front, regulatory authorities in the U.S. and Europe are in the process of reviewing an updated formulation of Pfizer’s vaccine, designed to target a specific subtype of the omicron variant.

Pfizer stands poised to swiftly distribute this adapted vaccine as soon as it receives regulatory authorization, in a bid to enhance its product offerings and potentially rejuvenate its sales trajectory.

For all the latest healthcare industry news from Africa and the World, subscribe to our NEWSLETTER, and YouTube Channel, follow us on Twitter and LinkedIn, and like us on Facebook.